Bolt Biotherapeutics, Inc. BOLT

BOLT Company Overview

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment. The company operates within the biotechnology and oncology therapeutics industries, with a primary emphasis on activating the innate and adaptive immune systems to generate anti-tumor responses. Bolt’s core platform is based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) technology, which combines tumor-targeting antibodies with immune-stimulatory agents designed to activate myeloid cells within the tumor microenvironment. The company’s revenue has historically been derived primarily from collaboration agreements, licensing arrangements, and research funding rather than commercialized product sales, as its therapeutic candidates remain in clinical development.

Bolt Biotherapeutics was founded in 2015 and is headquartered in Redwood City, California. The company evolved from early research focused on linking innate immune activation with antibody targeting approaches intended to improve the effectiveness of immuno-oncology therapies. Since its initial public offering in 2021, the company has continued advancing clinical-stage oncology candidates and refining its platform technologies. Bolt’s strategic positioning centers on addressing limitations associated with conventional checkpoint inhibitors and antibody therapies by enhancing localized immune activation while attempting to minimize systemic toxicity.